Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Remodulin (treprostinil) as add-on therapy for persistent pulmonary hypertension of the newborn
2023-001028-40Phase 2
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of treprostinil in persistent pulmonary hypertension of the newborn (PPHN) and pulmonary hypertension (PH), sponsored by United Therapeutics Corporation. Primary endpoint: Clinical worsening.
02
Drugs
treprostinil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2023-001028-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001028-40.